NCT07221773Enrolling by invitation
Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair
Pilot Study to Evaluate the Efficacy and Safety of Xvie (Human Amniotic Fluid Derived Nanoparticle Solution) Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair
In the register
The register attaches this trial to Xvie (amniotic fluid injectable) (Xtressé), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Enrolling by invitation
- Declared phase
- Not applicable (NA in the registry)
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
- Participants (registry)
- 15
- Start
- September 2025
- Primary completion
- December 2026 (planned)
- Study completion
- February 2027 (planned)
- Last registry update
- June 2026
- Countries
- United States
Conditions studied: Hair Thinning
Interventions: XVIE
Other trials of Xvie (amniotic fluid injectable)
XVIE to Treat Androgenetic Alopecia (AGA)
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.